DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Accolate (Zafirlukast) - Published Studies

 
 



Accolate Related Published Studies

Well-designed clinical trials related to Accolate (Zafirlukast)

The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. [2011.02]

Effects of zafirlukast on capsular contracture: controlled study measuring the mammary compliance. [2007.07]

[Nasal budesonide plus zafirlukast vs nasal budesonide plus loratadine-pseudoephedrine for controlling the symptoms of rhinitis and asthma] [2005.03]

Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. [2005.03]

Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma. [2005.02]

The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients. [2004.12]

Effect of the two different leukotriene receptor antagonists, montelukast and zafirlukast, on quality of life: a 12-week randomized study. [2004.11]

Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. [2004.11]

The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. [2004.01]

Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study. [2003.08]

A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis. [2003.03]

Zafirlukast has no beneficial effects in the treatment of chronic urticaria. [2002.12]

Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. [2002.07]

Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. [2002.06]

Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. [2002.05]

The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast. [2001.10]

Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. [2001.09]

A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. [2001.08.15]

Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. [2001.07.05]

Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. [2001.07]

[Influence of zafirlukast on pulmonary functions and quality of life in patients with asthma] [2001.06.28]

Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. [2001]

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. [2001]

Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. [2000.11]

Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. [2000.08]

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. [2000.06]

Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. [2000.06]

Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction. [2000.04]

A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. [2000.04]

Comparison of zafirlukast (Accolate) absorption after oral and colonic administration in humans. [2000.02]

Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma. [2000.02]

Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist. [2000]

The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness. [1999.12]

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. [1999.06]

Effect of zafirlukast on cough reflex sensitivity in asthmatics. [1999.05]

Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. [1999.05]

Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial. [1999.04]

The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. [1999.03]

Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma. [1999.02]

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. [1999.02]

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. [1998.12]

A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. [1998.07]

Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. [1998.05]

The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. [1997.12]

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. [1997.07]

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. [1997.02.01]

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. [1994.09]

Well-designed clinical trials possibly related to Accolate (Zafirlukast)

Cysteinyl-leukotriene receptor antagonism blunts the acute hypotensive response to endotoxin in cats. [2010.10]

The expanding role of leukotriene receptor antagonists in chronic asthma. [2006.12]

Efficacy of a leukotriene receptor antagonist in the treatment of perennial allergic rhinitis. [2006.04]

Effects of drug treatment on inflammation and hyperreactivity of airways and on immune variables in cats with experimentally induced asthma. [2005.07]

Daily versus as-needed corticosteroids for mild persistent asthma. [2005.04.14]

Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics. [2004.11]

Leukotriene modifier vs inhaled corticosteroid in mild-to-moderate asthma: clinical and anti-inflammatory effects. [2004.05]

Pycnogenol as an adjunct in the management of childhood asthma. [2004]

Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. [2002.07]

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. [2002.05]

Modulation of the immediate allergic wheal reaction in the skin by drugs inhibiting the effects of leukotriene C4 and prostaglandin D2. [2001.04]

Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. [2000.09]

Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. [2000.08.01]

Treatment preferences of adolescent patients with asthma. [2000.02]

Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. [1999.06]

Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness. [1999.05]

Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. [1997.06]

The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. [1995.06]

The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. [1994.02]

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. [1993.10]

Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. [1993.06]

The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. [1993.06]

Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. [1992.05]

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. [1992.04]

Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. [1991.05.04]

Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. [1991.03.23]

The effect of the oral leukotriene antagonist, ICI 204,219, on leukotriene D4 and histamine-induced cutaneous vascular reactions in man. [1991.01]

Other research related to Accolate (Zafirlukast)

Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. [2011.11.23]

Effect of combination of zafirlukast and quercetin on baroreflex sensitivity and endothelin production in rats with myocardial infarction. [2010.05]

Zafirlukast pocket delivery impairs the capsule healing around textured implants in rats. [2009.01]

The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma-A comparison with leukotriene D(4) induced broncoconstriction. [2008]

Reduction of capsular thickness around silicone breast implants by zafirlukast in rats. [2008]

Histologic analysis of zafirlukast's effect on capsule formation around silicone implants. [2007.09]

The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma-A comparison with leukotriene D(4) induced broncoconstriction. [2007.05.24]

[Treatment of asthmatic patients with zafirlukast] [2007.01]

Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England. [2007]

The effects of zafirlukast on capsular contracture: preliminary report. [2006.09]

Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. [2006.07]

Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast. [2006]

The combined effects of zafirlukast, prednisone, and inhaled budesonide on IL-13 and IFN-gamma secretion. [2005.09]

Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study. [2004.06]

Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. [2003.10]

Effects of zafirlukast on bronchial asthma and allergic rhinitis. [2003.06]

Effect of zafirlukast on methacholine and ultrasonically nebulized distilled water challenge in patients with mild asthma. [2003.05]

Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary disease. [2003]

Zafirlukast-induced acute hepatitis. [2002.11]

Vasculitis induced by zafirlukast therapy. [2002.08]

Pulmonary function changes and immunomodulation of cytokine expression by zafirlukast after sensitization and allergen challenge in brown Norway rats. [2002.06]

[Zafirlukast (Accolate): a review of its pharmacological and clinical profile] [2002.04]

[Aspirin induced asthma, urinary leukotriene E4 and zafirlukast] [2002.03]

[Zafirlukast in treatment of nasal polyps in patients with aspirin intolerant bronchial asthma--preliminary report] [2002.03]

Treatment of canine atopic dermatitis with zafirlukast, a leukotriene-receptor antagonist: a single-blinded, placebo-controlled study. [2002.03]

[Zafirlukast in treatment of nasal polyps in patients with aspirin intolerant bronchial asthma--preliminary report] [2002.03]

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. [2002.02]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017